Skip to content
VectorGene
zh
临床和技术内容以英语提供。

CHGB · Partner-reported service scope

Fecal Microbiota Transplantation (FMT)

FMT products in capsule and suspension form, recommended by clinical guidelines for recurrent or refractory Clostridioides difficile infection.

Method
Capsules · bacterial suspension
Empty hospital room and bed. Illustrative stock photograph.
Empty hospital room and bed

CHGB · Partner-reported

Service capabilities

The following scope is reported by the partner. Quantities describe the partner portfolio and do not represent VectorGene’s own track record.

Transplantation capsules
Multiple specifications.
Bacterial suspension
Multiple specifications.

Explore the related platform.

Metagenomic and targeted sequencing platforms for infectious disease diagnosis, outbreak surveillance and microbiome research at institutional or national scale.

Pathogen & Microbiome Sequencing
Varies by jurisdiction

Clinical use of metagenomic sequencing is regulated as a diagnostic and varies by jurisdiction. Surveillance and research applications typically sit under different frameworks.

Explore services in this category.

Read each service’s complete scope and regulatory note. These links help you explore the portfolio; programme-specific suitability requires feasibility assessment.

Define the indication and product pathway first.

FMT programme planning needs a specific indication, source and processing model. The institutional review should connect clinical governance with donor qualification, traceability, storage and safety oversight. Permissions and evidence for one use or supply model do not establish the position for another.

FDA’s FMT enforcement policy concerns limited circumstances involving C. difficile infection unresponsive to standard therapies. It addresses consent, donor and stool qualification, and safety, and does not extend to other uses or stool-bank products.

FDA: FMT enforcement policy · November 2022

External references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.

Questions for the programme brief

  1. Which use and supply model?

    Specify the indication, product source, processing scope and local authority requirements to be reviewed.

  2. How are materials qualified?

    Request donor and stool screening, handling, traceability and criteria for excluding material from use.

  3. Who oversees safety?

    Agree clinical review, consent, follow-up, adverse-event reporting and the response to a donor or product safety signal.

What to prepare for review
  • Indication and local governance brief
  • Product-source and qualification documentation
  • Traceability and safety-review proposal

Working environments

Clinical context and laboratory preparation.

Illustrative stock photography provides context for the people, processes and working environments behind this capability.

Clear culture dishes and laboratory glassware.
Culture dishes
Hospital room with bed and clinical equipment. Illustrative stock photograph.
Hospital room with bed and clinical equipment
Laboratory technician performing a barcode scan. Illustrative stock photograph.
Laboratory technician performing a barcode scan
Document review at a desk. Illustrative stock photograph.
Document review at a desk

Start a conversation

Discuss Fecal Microbiota Transplantation (FMT)

This service will be retained as context for your enquiry. Choose the platform or support area you want to develop at your institution.
Partner with us